These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9260828)

  • 41. [Associated risk factors of fatty liver in the patients with type 2 diabetes mellitus].
    Chen QK; Chen HY; Wang LY; Zeng ZY; Zhou XD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):414-6. PubMed ID: 15268806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical and genetic heterogeneity in hypobetalipoproteinemia].
    Pocovi M; Civeira F
    Med Clin (Barc); 2009 Jun; 133(2):61-2. PubMed ID: 19442997
    [No Abstract]   [Full Text] [Related]  

  • 43. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease.
    Komatsu M; Yazaki M; Tanaka N; Sano K; Hashimoto E; Takei Y; Song YZ; Tanaka E; Kiyosawa K; Saheki T; Aoyama T; Kobayashi K
    J Hepatol; 2008 Nov; 49(5):810-20. PubMed ID: 18620775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C and steatosis: a reappraisal.
    Lonardo A; Loria P; Adinolfi LE; Carulli N; Ruggiero G
    J Viral Hepat; 2006 Feb; 13(2):73-80. PubMed ID: 16436124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai].
    Fang JG; Zhu J; Li XJ; Li R; Dai F; Song XM; Chen L; Li F; Chen SY
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):83-8. PubMed ID: 15727689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Nonalcoholic fatty liver disease and insulin resistance: clinical, biochemical, and morphological parallels].
    Zvenigorodskaia LA; Drozdov VN; Egorova EG
    Eksp Klin Gastroenterol; 2008; (3):25-30. PubMed ID: 19145879
    [No Abstract]   [Full Text] [Related]  

  • 47. Chemotherapy-induced steatohepatitis in colorectal cancer patients.
    Gentilucci UV; Santini D; Vincenzi B; Fiori E; Picardi A; Tonini G
    J Clin Oncol; 2006 Dec; 24(34):5467; author reply 5467-8. PubMed ID: 17135651
    [No Abstract]   [Full Text] [Related]  

  • 48. Low LDL cholesterol-Friend or foe?
    Hartz J; Hegele RA; Wilson DP
    J Clin Lipidol; 2019; 13(3):367-373. PubMed ID: 31130490
    [No Abstract]   [Full Text] [Related]  

  • 49. Dysmorphic findings in two cases of abeta/hypobetalipoproteinemia.
    Solomon BD; Mohan P; Tifft CJ
    Clin Dysmorphol; 2009 Apr; 18(2):90-91. PubMed ID: 19282754
    [No Abstract]   [Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Vanhoye X; Janin A; Caillaud A; Rimbert A; Venet F; Gossez M; Dijk W; Marmontel O; Nony S; Chatelain C; Durand C; Lindenbaum P; Rieusset J; Cariou B; Moulin P; Di Filippo M
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance of APOB inactivation in hepatocellular carcinoma.
    Lee G; Jeong YS; Kim DW; Kwak MJ; Koh J; Joo EW; Lee JS; Kah S; Sim YE; Yim SY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30429453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.
    Hegele RA; Gidding SS; Ginsberg HN; McPherson R; Raal FJ; Rader DJ; Robinson JG; Welty FK
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2269-80. PubMed ID: 26376908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insights from human congenital disorders of intestinal lipid metabolism.
    Levy E
    J Lipid Res; 2015 May; 56(5):945-62. PubMed ID: 25387865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypobetalipoproteinemia and abetalipoproteinemia.
    Welty FK
    Curr Opin Lipidol; 2014 Jun; 25(3):161-8. PubMed ID: 24751931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.
    Cefalù AB; Pirruccello JP; Noto D; Gabriel S; Valenti V; Gupta N; Spina R; Tarugi P; Kathiresan S; Averna MR
    Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):2021-5. PubMed ID: 23723369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis.
    Lam MC; Singham J; Hegele RA; Riazy M; Hiob MA; Francis G; Steinbrecher UP
    Case Rep Gastroenterol; 2012 May; 6(2):429-37. PubMed ID: 22855658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heterozygous familial hypobetalipoproteinemia associated with fatty liver.
    Tarugi P; Lonardo A
    Am J Gastroenterol; 1997 Aug; 92(8):1400-2. PubMed ID: 9260828
    [No Abstract]   [Full Text] [Related]  

  • 59. Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1998 Dec; 93(12):2598-9. PubMed ID: 9860439
    [No Abstract]   [Full Text] [Related]  

  • 60. Fatty liver due to heterozygous hypobetalipoproteinemia.
    Wishingrad M; Paaso B; Garcia G
    Am J Gastroenterol; 1994 Jul; 89(7):1106-7. PubMed ID: 8017374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.